1. Home
  2. BRIA vs IMUX Comparison

BRIA vs IMUX Comparison

Compare BRIA & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRIA
  • IMUX
  • Stock Information
  • Founded
  • BRIA 2011
  • IMUX 2016
  • Country
  • BRIA Singapore
  • IMUX United States
  • Employees
  • BRIA N/A
  • IMUX N/A
  • Industry
  • BRIA
  • IMUX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BRIA
  • IMUX Health Care
  • Exchange
  • BRIA NYSE
  • IMUX Nasdaq
  • Market Cap
  • BRIA 86.3M
  • IMUX 86.3M
  • IPO Year
  • BRIA 2024
  • IMUX N/A
  • Fundamental
  • Price
  • BRIA $3.32
  • IMUX $1.00
  • Analyst Decision
  • BRIA
  • IMUX Strong Buy
  • Analyst Count
  • BRIA 0
  • IMUX 6
  • Target Price
  • BRIA N/A
  • IMUX $12.67
  • AVG Volume (30 Days)
  • BRIA 17.0K
  • IMUX 913.2K
  • Earning Date
  • BRIA 02-24-2025
  • IMUX 02-24-2025
  • Dividend Yield
  • BRIA N/A
  • IMUX N/A
  • EPS Growth
  • BRIA N/A
  • IMUX N/A
  • EPS
  • BRIA 92.24
  • IMUX N/A
  • Revenue
  • BRIA $55,755,669.00
  • IMUX N/A
  • Revenue This Year
  • BRIA N/A
  • IMUX N/A
  • Revenue Next Year
  • BRIA N/A
  • IMUX N/A
  • P/E Ratio
  • BRIA $0.04
  • IMUX N/A
  • Revenue Growth
  • BRIA 8.03
  • IMUX N/A
  • 52 Week Low
  • BRIA $2.90
  • IMUX $0.92
  • 52 Week High
  • BRIA $4.38
  • IMUX $2.11
  • Technical
  • Relative Strength Index (RSI)
  • BRIA N/A
  • IMUX 50.39
  • Support Level
  • BRIA N/A
  • IMUX $0.92
  • Resistance Level
  • BRIA N/A
  • IMUX $0.97
  • Average True Range (ATR)
  • BRIA 0.00
  • IMUX 0.06
  • MACD
  • BRIA 0.00
  • IMUX 0.01
  • Stochastic Oscillator
  • BRIA 0.00
  • IMUX 66.61

About BRIA BRILLIA INC

BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: